Questcor®

For assistance with any problem or issue, please contact customer service at 1.800.411.3065 (M-F from 8:00 a.m. to 4:00 p.m. Pacific Standard Time.)

In the event of an emergency, please contact us 24 hours a day, 7 days a week at 1.800.411.3065

Working for a small company like Questcor allows you the opportunity to express and implement your own unique ideas. The company encourages professional growth without boundaries.

-Christine T.
Acthar Specialist

Questcor's working environment has allowed me to be successful by offering an excellent management team, realistic attainable goals, and a competitive compensation plan.

-Doug D.
Regional Manager

Hard work, teamwork, and a can-do spirit personify the people and the culture at Questcor.

-Todd B.
Acthar Specialist

Working at Questcor has been a rewarding growth opportunity both personally and professionally. Over the years and through many changes in the company, it has been a great experience to work with so many talented people who are focused on improving the lives of patients suffering from CNS and inflammatory disorders.

-Heather B.
Market Research

This is a place where your ideas and opinions not only matter, but are encouraged. Truly unique, like no other company you will work for, a company with a very bright future.

-Matthew D.
Regional Manager

For me working at Questcor has been great. The company culture is excellent; I have a diversity of responsibilities, and most importantly I have very good work/life balance.

-Temi O.
Finance and Accounting

Research Initiatives

The following provides information on key indications for our marketed product H.P Acthar^® Gel. We are also exploring possible funding opportunities for exploratory studies in additional therapeutic areas having high unmet need.

Acthar is currently indicated to treat Nephrotic Syndrome (specifically 'to induce a diuresis or a remission of proteinuria in the Nephrotic Syndrome without uremia of the idiopathic type or that due to lupus erythamatosus'). We are working with leading nephrologists to further study the use of Acthar in the treatment of nephrotic syndrome.

We have also completed filing a supplemental New Drug Application (sNDA) for Acthar as a treatment for Infantile Spasms. There is currently no drug approved in the United States for the treatment of Infantile Spasms.